retatrutide amino acid sequence (LY3437943) | GCGR/GIPR/GLP-1R Agonist Retatrutide - Research Use Only

Description

doi:10.1177/2040622319862691

A 2023 study out of the University of British Columbia linked GLP-1 agonists to a heightened risk of severe gastrointestinal problems. These problems include gastroparesis, pancreatitis, and bowel obstruction

The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity), completed in 2023 with over 17,600 participants, demonstrated a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease and overweight or obesity but without diabetes

GLP-1 Medications and Kidney Transplant Eligibility In 2026, many transplant centers continue to encourage healthy weight management before kidney transplantation